Cytosorbents Corporation (CTSO): Price and Financial Metrics
CTSO Price/Volume Stats
Current price | $0.97 | 52-week high | $4.29 |
Prev. close | $0.88 | 52-week low | $0.84 |
Day low | $0.88 | Volume | 134,800 |
Day high | $0.99 | Avg. volume | 187,732 |
50-day MA | $0.98 | Dividend yield | N/A |
200-day MA | $1.99 | Market Cap | 42.93M |
CTSO Stock Price Chart Interactive Chart >
CTSO POWR Grades
- Value is the dimension where CTSO ranks best; there it ranks ahead of 70.68% of US stocks.
- CTSO's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
- CTSO's current lowest rank is in the Momentum metric (where it is better than 4.37% of US stocks).
CTSO Stock Summary
- With a market capitalization of $44,438,509, CYTOSORBENTS CORP has a greater market value than just 13.33% of US stocks.
- With a year-over-year growth in debt of 37.78%, CYTOSORBENTS CORP's debt growth rate surpasses 84.24% of about US stocks.
- In terms of volatility of its share price, CTSO is more volatile than 88.56% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to CYTOSORBENTS CORP are NTGR, DDD, IRBT, IDN, and SLGC.
- Visit CTSO's SEC page to see the company's official filings. To visit the company's web site, go to www.cytosorbents.com.
CTSO Valuation Summary
- In comparison to the median Healthcare stock, CTSO's price/sales ratio is 40.91% lower, now standing at 1.3.
- Over the past 195 months, CTSO's price/earnings ratio has gone down 0.8.
Below are key valuation metrics over time for CTSO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CTSO | 2023-12-29 | 1.3 | 2.7 | -2.1 | -2.3 |
CTSO | 2023-12-28 | 1.3 | 2.6 | -2.1 | -2.3 |
CTSO | 2023-12-27 | 2.0 | 3.9 | -3.1 | -3.3 |
CTSO | 2023-12-26 | 2.1 | 4.1 | -3.3 | -3.4 |
CTSO | 2023-12-22 | 2.1 | 4.2 | -3.3 | -3.5 |
CTSO | 2023-12-21 | 2.2 | 4.4 | -3.5 | -3.7 |
CTSO Growth Metrics
- Its 4 year net income to common stockholders growth rate is now at -55.35%.
- The 3 year net income to common stockholders growth rate now stands at -53.6%.
- Its 2 year net income to common stockholders growth rate is now at -64.61%.
The table below shows CTSO's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 36.08053 | -28.38555 | -41.35347 |
2022-06-30 | 37.72959 | -25.78428 | -35.55892 |
2022-03-31 | 41.2581 | -19.78053 | -29.35722 |
2021-12-31 | 43.16553 | -14.0056 | -24.55865 |
2021-09-30 | 44.33911 | -9.571806 | -15.92936 |
2021-06-30 | 45.1253 | -8.722604 | -10.3628 |
CTSO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CTSO has a Quality Grade of D, ranking ahead of 21.38% of graded US stocks.
- CTSO's asset turnover comes in at 0.475 -- ranking 101st of 186 Medical Equipment stocks.
- NVCR, CUTR, and HAE are the stocks whose asset turnover ratios are most correlated with CTSO.
The table below shows CTSO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.475 | 0.759 | -0.637 |
2021-03-31 | 0.518 | 0.734 | -0.733 |
2020-12-31 | 0.570 | 0.730 | -0.516 |
2020-09-30 | 0.648 | 0.709 | -0.613 |
2020-06-30 | 0.857 | 0.706 | -0.892 |
2020-03-31 | 0.884 | 0.719 | -0.911 |
CTSO Price Target
For more insight on analysts targets of CTSO, see our CTSO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $14.60 | Average Broker Recommendation | 1.33 (Strong Buy) |
Cytosorbents Corporation (CTSO) Company Bio
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Latest CTSO News From Around the Web
Below are the latest news stories about CYTOSORBENTS CORP that investors may wish to consider to help them evaluate CTSO as an investment opportunity.
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board RecommendationPRINCETON, N.J., Dec. 28, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announces an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board (“DSMB”) analysis for the pivotal U.S. and Canadian STAR-T (Safe and |
Insider Spends US$100k Buying More Shares In CytosorbentsInvestors who take an interest in Cytosorbents Corporation ( NASDAQ:CTSO ) should definitely note that the CEO... |
Insider Buying: CEO Phillip Chan Acquires 75,188 Shares of CytoSorbents Corp (CTSO)Recent insider trading activity has caught the attention of investors as Phillip Chan, CEO of CytoSorbents Corp, made a significant purchase of company shares. |
CytoSorbents Announces Closing of $10.3 Million Registered Direct OfferingCompany insiders participated in the transaction with $435,000 of investmentPRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announces the closing of its previously announced registered direct offering for the sale by the Company directly to investors of an aggregate of |
CTSO: CytoSorbents reports 3rd quarter 2023 financial and operating results which showed strong product revenue growth and an improved cost structure.By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 3rd quarter 2023 results on November 9th which showed strong product revenue growth. 3rd quarter product revenues increased 20% to $7.8 million and grant income decreased 35.9%. The increase in the Euro to U.S. dollar exchange rate positively impacted product sales by approximately $508,000. The |
CTSO Price Returns
1-mo | -3.96% |
3-mo | -45.20% |
6-mo | -51.74% |
1-year | -69.01% |
3-year | -89.27% |
5-year | -88.13% |
YTD | -12.61% |
2023 | -28.39% |
2022 | -63.01% |
2021 | -47.43% |
2020 | 107.01% |
2019 | -52.35% |
Continue Researching CTSO
Want to see what other sources are saying about Cytosorbents Corp's financials and stock price? Try the links below:Cytosorbents Corp (CTSO) Stock Price | Nasdaq
Cytosorbents Corp (CTSO) Stock Quote, History and News - Yahoo Finance
Cytosorbents Corp (CTSO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...